| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
CRANAD-2 targets amyloid-beta (Aβ) aggregates, specifically Aβ plaques. It acts as a fluorescent probe, binding to Aβ aggregates with high affinity (Kd = 38 nM). Upon binding, its fluorescence properties change, allowing for the detection and imaging of Aβ plaques. This makes it a valuable tool for studying Alzheimer's disease and other conditions involving Aβ aggregation.
|
|---|---|
| ln Vitro |
In vitro, CRANAD-2 has a high affinity for Aβ aggregates with a Kd of 38 nM. Upon binding to Aβ aggregates, it exhibits a 70-fold increase in fluorescence intensity, a 90 nm blue shift, and a large increase in quantum yield. These properties allow for sensitive detection of Aβ aggregates. It is a near-infrared (NIR) fluorescent probe with excitation and emission in the NIR region.
|
| ln Vivo |
In vivo, CRANAD-2 penetrates the blood-brain barrier and can be used for the detection of Aβ plaques in live animals. Upon interacting with Aβ aggregates, it undergoes changes in its fluorescence properties that allow for imaging. It has been used for in vivo detection of amyloid-beta deposits. Its NIR fluorescence allows for deep tissue imaging with minimal background autofluorescence.
|
| Enzyme Assay |
CRANAD-2 is characterized in cell-free systems for its photophysical properties and its affinity for Aβ aggregates. Its binding affinity (Kd) for Aβ aggregates is determined using fluorescence-based assays. The changes in fluorescence intensity, wavelength shift, and quantum yield upon binding are measured.
|
| Cell Assay |
CRANAD-2 is used in cell-based assays for imaging Aβ aggregates. Cells or tissues containing Aβ aggregates are incubated with CRANAD-2, and fluorescence imaging is performed to visualize the aggregates. However, specific cell-based assay protocols are not extensively documented. It is primarily used for in vivo imaging.
|
| Animal Protocol |
CRANAD-2 is administered intravenously in animal models, such as APP/PS1 transgenic mice, for in vivo imaging of Aβ plaques. Upon administration, it crosses the blood-brain barrier and binds to Aβ plaques, allowing for their detection using fluorescence imaging techniques. Its biodistribution and clearance are evaluated in these studies.
|
| ADME/Pharmacokinetics |
CRANAD-2 has a molecular formula of C23H25BF2N2O2 and a molecular weight of 410.26. Its CAS number is 1193447-34-5. The compound is a solid. It is soluble in DMSO. It should be stored under recommended conditions. It is also known as CRANAD 2.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is available for CRANAD-2. The compound is for research use only and is not intended for human therapeutic use. It is a fluorescent probe used for imaging Aβ plaques in Alzheimer's disease research.
|
| References |
|
| Additional Infomation |
CRANAD-2 is a near-infrared fluorescent probe specific for amyloid-beta plaques. It is a difluoroboron-based curcumin derivative. It is used for in vivo detection of amyloid-beta deposits. The compound is not approved for clinical use.
|
| Molecular Formula |
C23H25BF2N2O2
|
|---|---|
| Molecular Weight |
410.2718
|
| Exact Mass |
410.198
|
| Elemental Analysis |
C, 67.33; H, 6.14; B, 2.63; F, 9.26; N, 6.83; O, 7.80
|
| CAS # |
1193447-34-5
|
| PubChem CID |
90488972
|
| Appearance |
Brown to black solid powder
|
| LogP |
4.938
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
30
|
| Complexity |
777
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN(C1=CC=C(C=CC2=C/C(=C\C=C3C=CC(=[N+](C)C)C=C3)/O[B-](F)(F)O2)C=C1)C |c:14,20,29,t:2,4,6,8,12,16|
|
| InChi Key |
PVXQJYXODFZTBR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H25BF2N2O2/c1-27(2)20-11-5-18(6-12-20)9-15-22-17-23(30-24(25,26)29-22)16-10-19-7-13-21(14-8-19)28(3)4/h5-17H,1-4H3
|
| Chemical Name |
[4-[(2Z)-2-[6-[(E)-2-[4-(dimethylamino)phenyl]ethenyl]-2,2-difluoro-1,3-dioxa-2-boranuidacyclohex-5-en-4-ylidene]ethylidene]cyclohexa-2,5-dien-1-ylidene]-dimethylazanium
|
| Synonyms |
CRANAD2 CRANAD 2 CRANAD-2
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~2.5 mg/mL (~6.09 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4374 mL | 12.1871 mL | 24.3742 mL | |
| 5 mM | 0.4875 mL | 2.4374 mL | 4.8748 mL | |
| 10 mM | 0.2437 mL | 1.2187 mL | 2.4374 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
